Bioiberica Launched It. STADA Crossed Continents with It
Somewhere between that glass of red wine and the headache that followed, between the aged cheese and the inexplicable bloating, a clinically recognised condition was being missed. Histamine intolerance affects a significant portion of the adult population worldwide. Most of them have never been correctly diagnosed. They have been told to avoid wine, cut out fermented foods, and live with the discomfort. What they actually need is a single enzyme their gut stopped producing in sufficient quantities. That enzyme now has three serious commercial champions, and the race to own this market is accelerating fast.
What Bioiberica, STADA, and AB Biotek Did in 12 Months
- Bioiberica S.A.U. (Spain) launched DAOgest in July 2024, a clinically validated branded ingredient designed specifically to break down dietary histamine before it enters the bloodstream. It is the most rigorously positioned DAO product to reach the commercial supplement market and signals that major life sciences companies now view histamine intolerance as a mainstream addressable condition.
- STADA Arzneimittel AG (Germany) partnered with NEXGEL to bring its European flagship DAO supplement Histasolv into North America in June 2024, the first time a clinically established European DAO brand has crossed into the U.S. and Canadian market through a formal commercial agreement.
- AB Biotek released adiDAO Microencapsulated in April 2024, solving a technical problem that had limited the category for years. For the first time, DAO enzyme can be combined with other functional ingredients in a single formulation without degrading, opening an entirely new product design space for supplement manufacturers.
- Seeking Health, Pure Encapsulations, and XYMOGEN are all expanding their DAO supplement lines in 2025, responding to rapidly growing consumer self-identification with histamine-related symptoms through online health communities and functional medicine practitioners.
The Market Insight Nobody Is Talking About
Fewer than 10% of general practitioners globally could identify DAO deficiency as a contributing factor to gastrointestinal complaints as of 2023. Only 12% of consumers had ever heard of DAO supplementation. This is not a market with a demand problem. It is a market with an awareness problem, and awareness problems in healthcare resolve in one direction: upward, and quickly once clinical and consumer education begins to scale.
The most commercially significant development is happening in Asia-Pacific. Fermented food cultures across China, Japan, South Korea, and Southeast Asia mean dietary histamine intake in these populations is structurally higher than in Western markets. As health supplement adoption accelerates across the region, DAO is positioned to move from specialist product to mainstream digestive health staple faster than anywhere else on earth. The brands establishing distribution and clinical credibility in Asia-Pacific right now are building the most defensible position in this category.
Strategic Market Intelligence
Explore the full competitive and forecast analysis: